Thus, suppressing/inhibiting D2R with an antagonist would decrease HTT protein aggregation and reduce cell death via striatal protection, which may be beneficial in the treatment of early-stage HD and could potentially delay disease progression [70]. This evidence concerns the gene DRD2 and Huntington disease.